Numerous studies have demonstrated the anti-proliferative or anti-angiogenic potential of ABL kinase inhibitors in several neoplasms, including breast [60, 61], ovarian [62] and lung [59] cancer cells in an ABL, PDGFR or c-Kit specific manner. This evidence concerns the gene KIT and neoplasm.